This review highlights the critical gaps in evidence regarding antiplatelet therapy in women and emphasizes the need to investigate sex-specific approaches in cardiovascular care.
Answers are grounded in this paper and cite their sources.
Does not support sex-specific antiplatelet adjustments in practice; leaves open critical evidence gaps for dedicated trials in women.
Antiplatelet therapy is a cornerstone of secondary prevention of cardiovascular diseases (CVDs). However, current guidelines are based on data derived primarily from men, as women are generally underrepresented in trials. Consequently, there are insufficient and inconsistent data on the effect of antiplatelet drugs in women. Sex differences were reported in platelet reactivity, patient management, and clinical outcomes after treatment with aspirin, P2Y₁₂ inhibitor, or dual antiplatelet therapy. To evaluate whether sex-specific antiplatelet therapy is needed, in this review we discuss (i) how sex affects platelet biology and response to antiplatelet agents, (ii) how sex and gender differences translate into clinical challenges and (iii) how the cardiological care in women might be improved. Finally, we highlight the challenges faced in clinical practice regarding the different needs and characteristics of female and male patients with CVD and address issues requiring further investigation.
No takes yet. Share an insight, caveat, or question.
Gąsecka et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: